🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psoriasis

Recruitingn/aAges 18 Years - anyAllIstanbul Training and Research Hospital
NCT07844772 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to better understand whether blood levels of Substance P are related to pain, itching, altered pain sensations, central sensitization, psoriasis severity, and quality of life in adults with chronic plaque psoriasis. The main questions this study aims to answer are: Are serum Substance P levels associated with neuropathic pain features, central sensitization, psoriasis severity, pain, itching, and quality of life? Do serum Substance P levels and these clinical features differ among patients receiving different psoriasis treatments? Researchers will compare three groups of patients: those receiving IL-17 inhibitor treatment, those receiving conventional systemic treatment with methotrexate or acitretin, and those receiving topical treatment only or no current treatment. Participants will: Have their psoriasis severity assessed and complete quest

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥18 years * Diagnosis of chronic plaque psoriasis * Ability and willingness to provide written informed consent * For the IL-17 inhibitor group: current treatment with an IL-17 inhibitor for at least 8 weeks * For the conventional systemic therapy group: current treatment with methotrexate or acitretin for at least 6 weeks * For the topical therapy/treatment-naive group: topical therapy only or no previous treatment, with no systemic therapy, biologic therapy, or phototherapy within the previous 6 months Exclusion Criteria: * Known diabetes mellitus, HbA1c ≥6.5%, or fasting plasma glucose ≥126 mg/dL * Vitamin B12 level \<200 pg/mL * Known peripheral neuropathy or peripheral neuropathy detected during neurological evaluation and/or electromyography * Neuropathy related to uremia or thyroid disease * Chronic renal failure or chronic liver failure * Active infection * Active malignancy * Active inflammatory arthritis in patients with psoriatic arthritis * Pregnancy or breastfeeding * Chronic heavy alcohol use
💊

What it tests

  • IL-17 Inhibitor Therapy
  • Conventional Systemic Therapy
📍

Where

1 site
Istanbul Training and Research Hospital
Istanbul, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy